Invité Mer 29 Juin 2011 - 11:46Eh ben, on n'a plus q'à avaler "XAV939" !!!
http://www.ncbi.nlm.nih.gov/pubmed?term=axin2%20multiple%20sclerosis
http://www.radio-canada.ca/nouvelles/Science-Sante/2011/06/28/002-sclerose-plaques-traitement.shtml
2 participants
Axin2
Invité- Invité
Eh ben, on n'a plus q'à avaler "XAV939" !!!
http://www.ncbi.nlm.nih.gov/pubmed?term=axin2%20multiple%20sclerosis
http://www.radio-canada.ca/nouvelles/Science-Sante/2011/06/28/002-sclerose-plaques-traitement.shtml
izuba- Messages : 523
Date d'inscription : 28/04/2010
VITE VITE
http://blog.santelog.com/2011/06/29/sclerose-en-plaques-decouverte-daxin2-la-proteine-qui-protege-la-myeline-nature-neuroscience/
http://blog.santelog.com/2011/06/29/sclerose-en-plaques-decouverte-daxin2-la-proteine-qui-protege-la-myeline-nature-neuroscience/
JCharles- Messages : 122
Date d'inscription : 02/05/2010
Age : 61
Localisation : Touraine
oui d'accord, mais dans combien d'années ???
Invité- Invité
J'ai l'article.
XAV machin chose a été directement injecté ds les lésions de moelle épinière de souris ! On n'est pas arrivé !
Injection of 0.1 μM XAV939 into demyelinated lesions in young adult mouse spinal cord at the time of lysolecithin injection produced significant increases in the appearance of PLP mRNA–expressing mature oligodendrocytes at 6 dpl in dorsal or ventral funicular lesions compared with vehicle-treated controls. (b) XAV939 effects were Axin2 dependent, as Axin2−/− mice showed significantly less OLP differentiation at 6 dpl following XAV and lysolecithin treatment versus controls.
Sujets similaires
|
|
|